The PI3K/AKT pathway has been identified to be a major contributor of 5-FU resistance in lung cancer; the potential therapeutic targeting of this pathway in an effort to reverse resistance has been widely reported [14,15]. This evidence concerns the gene AKT1 and lung carcinoma.